Changes in gastric mucosa and luminal environment during acid-suppressive therapy: A review in depth

Digestive and Liver Disease

Volumn 33, Issue 8, 2001, Pages 707-719

  Sanduleanu, S ^a   Jonkers, D ^a   De Bruine A ^a   Hameeteman, W ^a   Stockbrugger R W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acid inhibition; Chronic athropic gastritis; Enterochromaffin like cell hyperplasia; Helicobacter pylori

Indexed keywords

ANTACID AGENT; CIMETIDINE; CYANOCOBALAMIN; FAT; GASTRIN ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MINERAL; NITROSAMINE; OMEPRAZOLE; PD 136450; PROTON PUMP INHIBITOR; RANITIDINE; UNCLASSIFIED DRUG;

ATROPHY; BACTERIAL GROWTH; CELL HYPERPLASIA; DISEASE COURSE; ENTEROCHROMAFFIN CELL; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RISK; INTESTINE INFECTION; LONG TERM CARE; MALIGNANT TRANSFORMATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STOMACH ABSORPTION; STOMACH ACID; STOMACH ANTRUM; STOMACH FUNDUS; STOMACH GLAND; STOMACH MUCOSA; SUPERINFECTION;

EID: 0035204361     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80050-5     Document Type: Review

References (200)

1. Pathology of endocrine cells in gastric mucosa
2. Ultrastructure of a neuroendocrine complex in oxyntic mucosa of normal stomach
3. Structure and function of endocrine cells in the oxyntic (acid-secreting) mucosa of human stomach
4. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach
5. The achlorhydria-carcinoid sequence. Role of gastrin
6. Proposed mechanism of induction of gastric carcinoids. The gastrin hypothesis
7. 2 blockade and gastric carcinoid tumours in the rat
8. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats
9. Proliferation of enterochromaffin-like cells in omeprazole treated hypergastrinemic rats
10. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine
11. Proliferation of endocrine cells in the rat stomach caused by drug-induced achlorhydria
12. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like carcinoids in the rat
13. 15)-gastrin-17 in the rat
14. Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria
15. Serum gastrin levels during long-term omeprazole treatment
16. Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria
17. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole
18. Efficacy and safety of long-term treatment with omeprazole in patients with acid-related diseases resistant to ranitidine
19. Ultrastructural morphometry and gastric endocrine cells before and after omeprazole
20. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
21. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
22. Argyrophil cell hyperplasia of fundic mucosa in patients with chronic atrophic gastritis
23. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia
24. Morphology and natural history of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis
25. Gastric endocrine cell behaviour in Zollinger-Ellison patients upon long-term potent antisecretory treatment
26. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association
27. Influence of multiple endocrine neoplasia type-1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome
28. Is hypergastrinaemia dangerous to man?
29. Clinical significance of hypergastrinaemia: Relevance to gastrin monitoring during omeprazole therapy
30. Gastrinphysiological and pathophysiological role: Clinical consequences
31. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment
32. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men
33. Influence of Helicobacter pylori, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers
34. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
35. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: Implications for long-term safety
36. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
37. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
38. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa
39. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis
40. Considerations for long-term use of proton-pump inhibitors
41. Review article: Potential gastroentestinal effects of long-term acid suppression with proton pump inhibitors
42. Personal review: Is profound acid inhibition safe?
43. Personal review: Alarmism or legitimate concerns about long-term suppression of gastric acid secretion?
44. 2 receptor antagonist and proton pump inhibitor
45. Influence of gastric pH on gastric and jejunal flora
46. Studies on the intestinal flora. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons
47. Gastric acid barrier to ingested microorganisms in man: Studies in vivo and in vitro
48. Bactericidal factors in gastric juice
49. Pernicious anaemia, intragastric bacterial overgrowth and possible consequences
50. Bacterial overgrowth as a consequence of reduced gastric acidity
51. Bacterial colonization and nitrite concentration in the achlorhydric stomachs of patients with primary hypogammaglobulinaemia or classical pernicious anaemia
52. The microflora of the postoperative stomach
53. 2) breath test and gastric bacteria in acid-secreting subjects and in achlorhydria and post-gastrectomy patients before and after antimicrobial treatment
54. The microflora of the gastric juice after Billroth I and Billroth II partial gastrectomy
55. Effects of one year's treatment with ranitidine and of truncal vagotomy on gastric contents
56. Carcinoma and intestinal metaplasia of the stomach in Columbian migrants
57. Helicobacter pylori and non-Helicobacter pylori bacterial flora in gastric mucosal and tumour specimens of patients with primary gastric lymphoma
58. Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative
59. Bacteria in the aetio-pathogenesis of gastric cancer: A review
60. Effects of acid suppression on microbial flora of upper gut
61. Infective gastroenteritis and its relationship to reduced gastric acidity
62. The relationship between gastric secretion and infection
63. Hypochlorhydria and vulnerability to intestinal infection
64. Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs
65. 2 antagonists and antibiotics and gastric surgery as risk factors for salmonella infection
66. Omeprazole as a risk factor for campylobacter gastroenteritis: Case-control study
67. Relationship of the intestinal bacterial flora to absorption
68. Bacterial overgrowth syndrome without "blind loops": A cause for malnutrition in the elderly
69. Microflora and deconjugation of bile acids in alkaline reflux after partial gastrectomy
70. The bacterial overgrowth syndrome is uncommon in pernicious anaemia
71. Metabolic consequences of reduced gastric acidity
72. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects
73. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans
74. 12 during prolonged omeprazole therapy
75. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration
76. 12)
77. 12 absorption
78. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin
79. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole
80. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin
81. N-nitrosamine formation by intestinal bacteria
82. An investigation of the endogenous formation of apparent total N-nitroso compounds in conventional microflora and germ-free rats
83. Effects of acid suppression on microbial flora of upper gut
84. Bacterially catalysed N-nitrosation reactions and their relative importance in the human stomach
85. N-nitroso compounds in fresh gastric juice and their relation to intragastric pH and nitrite employing an improved analytical method
86. The etiology of gastric cancer: Intragastric nitrosamide formation and other theories
87. Nitrates, nitrites and gastric cancer in Great Britain
88. The experimental basis for the role of nitroso compounds in human cancer
89. Mechanisms of gastric carcinogenesis
90. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment
91. Intragastric bacterial activity and nitrosation during, and after treatment with omeprazole
92. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds
93. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study
94. Intragastric bacterial growth, nitrates, nitrites, and N-nitroso compounds after 300 mg ranitidine b.d., 20 mg omeprazole, 40 mg omeprazole and placebo
95. The effect of intragastric acidity and flora on the concentration of N-nitroso compounds in the stomach
96. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation
97. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice
98. N-nitrosation of medicinal drugs catalysed by bacteria from human saliva and gastro-intestinal tract, including Helicobacter pylori
99. Nitrosation of amines by stimulated macrophages
100. Neutrophil-mediated nitrosamine formation. Role of nitric oxide in rats
101. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
102. Attempt to fulfill Koch's postulates for pyloric Campylobacter
103. Ingestion of Campylobacter pyloridis causes gastritis and raised gastric juice pH
104. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment
105. Helicobacter pylori and peptic ulceration; histopathological aspects
106. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
107. The relationships between chronic gastritis and gastric acid secretion
108. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy
109. Helicobacter pylori gastritis and gastric physiology
110. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
111. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
112. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
113. Helicobacter pylori infection and chronic gastric acid hyposecretion
114. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: A prospective study
115. Improved fold width and increase acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis
116. Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease
117. Campylobacter pylori and duodenal ulcers: The gastrin link
118. Mucosal tumor necrosis factor-α, interleukin-1β, and interleukin-8 production in patients with Helicobacter pylori infection
119. Secretagogue-specific effects of interleukin-1 on gastric acid secretion
120. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line Gastroenterology
121. Effect of a Campylobacter pylori protein on acid secretion by parietal cells
122. Production of two chemically distinct acid-inhibitory factors by Helicobacter pylori
123. +-ATPase
124. Acid, ulcers, and H. pylori
125. Helicobacter pylori in dyspeptic patients: Quantitative association with severity of gastritis, intragastric pH, and serum gastrin concentration
126. Distribution of Helicobacter pylori colonisation and associated gastric inflammatory changes: Difference between patients with duodenal and gastric ulcers
127. Local acid production and Helicobacter pylori: A unifying hypothesis
128. A reappraissal of the nature and significance of chronic atrophic gastritis
129. The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens
130. The classification of chronic gastritis: Current status
131. Pathology of chronic gastritis and duodenitis
132. The Sydney System: Histological division
133. Sydney system: Epidemiology and natural history of chronic gastritis
134. The Sydney system: A new classification of gastritis
135. Classification and grading of gastritis. The up-dated Sydney system
136. Are there three types of Helicobacter pylori gastritis?
137. Observer variation in the assessment of chronic gastritis according to the Sydney system
138. Recognizing atrophy: Another step toward a classification of gastritis
139. Can atrophic gastritis be diagnosed in the presence of Helicobacter pylori infection?
140. The gastric transitional zones: Neglected links between gastroduodenal pathology and Helicobacter ecology
141. The importance of urease in acid protection for the gastric-colonising bacteria H. pylori and H. felis sp. nov
142. The effect of environmental pH on the proton motive force of H. pylori
143. Influence of pH on metabolism and urease activity of Helicobacter pylori
144. +-gated urea channel: The link between Helicobacter pylori urease and gastric colonization
145. Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease
146. Changes in the intragastric distribution of H. pylori during treatment with omeprazole
147. Effect of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients
148. Omeprazole therapy modifies the gastric localization of Helicobacter pylori
149. Effect of omeprazole on duodenal ulcer associated antral gastritis and Helicobacter pylori
150. A histological study of gastric mucosa before and after proximal vagotomy in duodenal ulcer patients
151. Morphology and function of the parietal cells after proximal selective vagotomy in duodenal ulcer patients
152. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients
153. Long-term observation of subjects with normal mucosa and with superficial gastritis: Results of a 23-27 years' follow-up examinations
154. Gastric precancerous process in a high risk population: Cohort follow-up
155. Chronic gastritis: Progression of inflammation and atrophy in a six-year follow-up of a random sample of 142 Estonian urban subjects
156. Long-term follow-up of Helicobacter pylori associated gastritis
157. Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in duodenal ulcer disease
158. 2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients
159. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
160. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease
161. Changing patterns of H. pylori gastritis in long-standing acid suppression
162. Review article: The development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy
163. Histology and safety parameters during long-term maintenance treatment with pantozole in severe acid-peptic disease
164. Lack of effect of acid suppression therapy on gastric atrophy
165. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls
166. Helicobacter pylori effects on gastritis, gastrin enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole
167. Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients
168. Helicobacter pylori eradication vs short-term acid suppression: Long term consequences for gastric body mucosa
169. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients
170. Gastric cancer risk in chronic atrophic gastritis: Statistical calculations of cross-sectional data
171. Omeprazole and accelerated onset of atrophic gastritis
172. Omeprazole and accelerated onset of atrophic gastritis
173. Omeprazole and accelerated onset of atrophic gastritis
174. Lack of effect of acid suppression therapy on gastric atrophy
175. Long-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori-positive patients
176. Effect of Helicobacter pylori eradication
177. On atrophy of the stomach
178. Helicobacter pylori and atrophic gastritis: Importance of the cagA status
179. Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: The role of cagA status
180. An 18-year follow-up study of chronic gastritis and Helicobacter pylori: Association of cagA positivity with development of atrophy and activity of gastritis
181. Clinical and histological association of cagA and vacA genotypes in Helicobacter pylori gastritis
182. Interleukin-1 polymorphisms associated with increased risk of gastric cancer
183. Intestinal metaplasia in Japan: Aassociation with diet
184. Cigarette smoking and other risk factors for progression of precancerous stomach lesions
185. The relationships between chronic gastritis and gastric acid secretion
186. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury
187. Mechanism of gastric mucosal damage induced by ammonia
188. Cytotoxicity of Helicobacter pylori on human gastric epithelial cells in vitro: Role of cytotoxin(s) and ammonia
189. Myeloperoxidase content and hypochlorous anion production increased in H. pylori-infected corpus mucosa after PPI treatment
190. Effects of ammonia, hypochloric acid on gastric mucosal barrier function at different luminal pH
191. Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol
192. Effects of acetaldehyde on cell regeneration and differentiation of the upper gastrointestinal tract mucosa
193. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa
194. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
195. Antigastric autoantibodies in Helicobacter pylori infection: Implications of histological and clinical parameters of gastritis
196. +-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy
197. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
198. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer